Synonyms: RMC-6291 | RMC6291
Compound class:
Synthetic organic
Comment: RMC-6291 is a KRASG12C(ON) inhibitor [2], that inhibits active, GTP-bound RAS. It is designed to bind to the immunophilin cyclophilin A (PPIA) via a moiety containing a minimal cyclophilin A-binding motif of the naturally ocurring immunosuppressive (cyclophilin inhibiting) polyketide Sanglifehrin A. It also contains a cysteine-reactive warhead to mediate covalent tethering to KRAS. The resulting RMC-6291:cyclophilin A structure has high affinity for the active state of KRASG12C and forms a RMC-6291:cyclophilin A:KRASG12C tri-complex that causes steric hindrance for RAS effector binding thus blocking oncogenic signalling. The chemical structure of RMC-6291 was disclosed during the 'First Disclosures of New Drug Candidates' session at the April 2023 meeting of the AACR in Orlando. The chemical structure of RMC-6291 is identical to that for the INN elironrasib (proposed list 132, Feb. 2025) and as disclosed in Cregg et al. (2025) [1].
RMC-6291 was developed for anti-tumour potential. |
|
Classification ![]() |
|
Compound class | Synthetic organic |
International Nonproprietary Names ![]() |
|
INN number | INN |
13269 | elironrasib |
Synonyms ![]() |
RMC-6291 | RMC6291 |
Database Links ![]() |
|
CAS Registry No. | 2641998-63-0 (source: WHO INN record) |
ChEMBL Ligand | CHEMBL5437500 |
GtoPdb PubChem SID | 479821412 |
PubChem CID | 167993669 |
Search Google for chemical match using the InChIKey | HJNFYLSFWYRSHS-JVFAQLKDSA-N |
Search Google for chemicals with the same backbone | HJNFYLSFWYRSHS |
Search PubMed clinical trials | elironrasib |
Search PubMed titles | elironrasib |
Search PubMed titles/abstracts | elironrasib |
UniChem Compound Search for chemical match using the InChIKey | HJNFYLSFWYRSHS-JVFAQLKDSA-N |
UniChem Connectivity Search for chemical match using the InChIKey | HJNFYLSFWYRSHS-JVFAQLKDSA-N |